OSI-7836 is a member of the nucleoside class of cytotoxic drugs of which gemcitabine is the market leader. OSI Pharmaceuticals develops OSI-7836 as a next-generation gemcitabine. The anti-tumor activity of... The anti-tumor activity of OSI-7836 appeares to be less schedule dependent than gemcitabine.
- Mechanism
- Curator reviewed
OSI-7836 appears to have a different mechanism of tumor growth inhibition blocking the cell division cycle at a different point (the G2 phase) than gemcitabine. The mechanism of action involves phosphorylation to the triphosphate form followed by incorporation into cellular DNA, leading to cell death.
- Primary indication
- Investigated for use/treatment in solid tumors.Curator reviewed
- Formula / weight
- C9H14ClN3O5S · 311.743 g/mol (avg)
- Code names
- OSI-7836
Resolves to
RCWYXGAOCMUXHG-ZXBIKLPVSA-NSMILESCl.NC1=NC(=S)N(C=C1)[C@]1(O)O[C@H](CO)[C@@H](O)[C@@H]1OWhat you can answer from here — as of April 02, 2025
Which companies are running trials of OSI-7836, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account